BELLUS Health, a biopharmaceutical company developing therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, announced topline results from its Phase 2 RELIEF trial of BLU-5937 (a P2X3 antagonist) in patients with refractory chronic cough.
Disappointingly, this Phase 2 trial did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency. However, statistically significant placebo adjusted reductions in cough frequency was achieved in a pre-specified sub-group of high cough count patients.
BLU-5937 was well tolerated with no serious adverse events reported and with low impact on taste perception.
The company plans to move BLU-5937 forward into an adaptive Phase 2b trial enriched for higher cough count patients.
Read more about BELLUS Health here.
Photo by Online Marketing on Unsplash
